University of Laval Partner Medicago In Hot Pursuit COVID-19 Vaccine Candidate in Canada

University of Laval Partner Medicago In Hot Pursuit COVID-19 Vaccine Candidate in Canada

Quebec-City-based Medicago, a subsidiary to Japan-based Mitsubishi Tanabe Pharma, reports a breakthrough in the fight against the coronavirus outbreak, making a claim that it has developed a COVID-19 vaccine candidate that could begin human testing as early as this summer. The venture reports it has produced a virus-like particle of the novel coronavirus, a first step toward producing a vaccine, which will now commence pre-clinical testing for safety and efficacy.

Who is Medicago?

Founded back in 1997, Medicago formed a partnership between Agriculture and Agri-Food Canada and the University of Laval, the company’s majority shares were acquired by Japanese company Mitsubishi Tanabe Pharma in 2013. They are a biotech company focusing on the research, development, production, and commercialization of vaccines in Canada. They develop vaccines based on their proprietary technologies, including the plant-based Proficia technology and Virus-Like Particles (VLP) technology. They have a number of collaborative agreements in place, including with Viridis S.A. and Philip Morris International.

Medicago Vaccine Success Track Record

Medicago is a leader in plant-based technology, ha...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee